• Introducción
  • CART19 for relapsed/refractory ALL: UPenn
  • CART19 for relapsed/refractory adult ALL: MSKCC
  • CART19 for relapsed/refractory adult ALL: FHCRC
  • Case vignette
  • Problems associated with CART19 therapy
  • CD19 antigen loss: alternative splicing
  • CD19 antigen loss: CD19 mutations
  • Possible solution/prevention: multiple/dual CARTs
  • Permanent B-cell aplasia
  • Cytokine release syndrome
  • Possible solution/prevention for CRS
  • Possible solution/prevention for lack of efficacy (without antigen loss)
  • Possible solution/prevention for lack of autologous T-cells
  • Possible solution/prevention for risks associated to genetic manipulation
  • Possible ways of reducing costs
  • Conclusiones